article Open AccessTop 1% cited
Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan
British Journal of Cancer · 2010 · Vol. 103(4) · pp. 469–474
Takuji Okusaka✉(National Cancer Center)Kohei Nakachi(National Cancer Center Hospital East)Akira Fukutomi(Shizuoka Cancer Center)Nobumasa Mizuno(Aichi Cancer Center)S. Ohkawa(Kanagawa Prefectural Hospital Organization)A Funakoshi(National Hospital Organization Kyushu Cancer Center)Masato Nagino(Nagoya University)Satoshi Kondo(Hokkaido University)Soshi Nagaoka(Eli Lilly (Japan))Jumpei Funai(Eli Lilly (Japan))Minori Koshiji(Eli Lilly (Japan))Yoshihiro Nambu(Eli Lilly (Japan))Junji Furuse(Kyorin University)Masaru Miyazaki(Chiba University)Y Nimura(Aichi Cancer Center)
Abstract
Gemcitabine plus cisplatin combination therapy was found to be effective and well tolerated, suggesting that it could also be a standard regimen for Japanese patients.
Cholangiocarcinoma and Gallbladder Cancer StudiesGallbladder and Bile Duct DisordersPediatric Hepatobiliary Diseases and TreatmentsGemcitabineMedicineNeutropeniaLeukopeniaInternal medicineRegimenCisplatinGastroenterologyCombination therapyFebrile neutropenia
MeSH terms
GemcitabineAdultAgedAged, 80 and overAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsBiliary Tract NeoplasmsCisplatinDeoxycytidineFemaleHumansJapanMaleMiddle AgedTreatment Outcome
Funding
- Eli Lilly and Company
- Eli Lilly Japan
Citations
740
FWCI
20.76
field-weighted impact
References
24
Percentile
100%
vs. same field & year
Citations per year
Cited by
Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma
Journal of Hepatology · 2014 · 1,526 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.